**MINUTES**

**CPIC CONFERENCE CALL**

**ST. JUDE CHILDREN'S RESEARCH HOSPITAL**

**DATE:** Sept 2nd, 2010

**PRESENT:** Russ Altman, Uli Broeckel, Michelle Carrillo, Kristine Crews, Felix Frueh, Matt Goetz, Andrea Gaedigk, James Hoffman, Julie Johnson, Grace Kuo, Rochelle Long, Michael Metzker, Audrey Papp, Mary Relling, Dan Roden, Wolfgang Sadee, Steven Scherer, Stuart Scott, Alan Shuldiner, Todd Skaar, Mike Stein, Rachel Tyndale, Sook Wah Yee, Issam Zineh

| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| --- | --- | --- |
| Reminder of PurposeUpdate on CPIC comments to NIH's proposed GTRCPIC publications: CPT special issueUpdate on 2C19/ clopidogrel guidelineCYP2D6 update | Since several new members have joined the group recently, Mary reminded the group of the purpose of CPIC. The current focus is development of specific gene/drug guidelines; however, defining the criteria by which clinicians judge pharmacogenetic evidence is another goal of CPIC.CPIC comments on GTR sent to NIH on August 5th; posted on Googlegroups. Rochelle indicated that she did receive confirmation that CPIC’s comments had been received.Mary updated the group that she and Teri have written an overview of CPIC for a special CPT issue on pharmacogenetics and that they will post a draft prior to its due date in September for comments.Alan Shuldiner led a discussion on the proposed Clopidogrel /2C19 guidelines, with a great deal of discussion on 2 recent articles (NEJM and Lancet) that purport to call into question importance of CYP2C19. It was the general consensus that the recent controversy makes it even more important that CPIC move forward on its 2C19/clopidogrel document. Several on the call expressed interest and support for the document. It was mentioned that soliciting real input and authorship from non-CPIC experts in the field is an option. The new data may require a more detailed guideline than originally planned. Platelet aggregation testing may also need to be considered as part of the guideline. Todd circulated slides illustrating possible options that he and Andrea have developed for illustrating the relationship between activity scores and CYP2D6 alleles and how to construct phenotypes from CYP2D6 allele scores. The group gave feedback and suggested that there be at least some simplification of the phenotypes into poor metabolizer, ultrarapid, and everything else, as these are the phenotypes likely to be actionable by clinicians. The discussion raised the point that the gene summary needs to linked to the dosing of at least one drug, which will facilitate structuring the genotype summaries. | Volunteers for summarizing criteria used by clinicians are welcome.Rochelle or Mary will let group know of any further response.Mary and Teri have since posted the draft and received comments that will be incorporated.Alan will continue to work on a draft and circulate to CPIC members, asking for additional input from co-authors.Todd and Andrea will try to finalize the gene summary and circulate to other authors for clinical input on medications. Matt Goetz volunteered to help with the medication portion of the CYP2D6 guideline.  |